Arcellx CMO reports sales totaling 3,643 shares via 10b5-1 plan
Rhea-AI Filing Summary
Heery Christopher, Chief Medical Officer of Arcellx, Inc. (ACLX), reported sales of company common stock under a Rule 10b5-1 trading plan. On 09/18/2025 he sold 3,343 shares at a weighted average price of $80.0085, leaving him with 34,427 shares beneficially owned after that transaction. On 09/19/2025 he sold an additional 300 shares at $80.00, leaving 34,127 shares beneficially owned. The Form 4 was signed by an attorney-in-fact on 09/19/2025.
The filing notes the sales were effected pursuant to a 10b5-1 plan entered March 23, 2025, and that the post-transaction totals include 284 shares acquired under the issuer's 2022 Employee Stock Purchase Plan on May 14, 2025. No derivative transactions or other changes were reported.
Positive
- None.
Negative
- None.
Insights
TL;DR: Insider sales under a pre-established 10b5-1 plan, modest in size relative to total holdings reported.
The reporting person, the Chief Medical Officer, executed two small open-market disposals totaling 3,643 shares at approximately $80 per share under a 10b5-1 plan dated March 23, 2025. The disclosure clarifies the weighted-average price and that the holdings include recent ESPP-acquired shares. This is a routine compliance disclosure; the 10b5-1 plan provides a non-speculative rationale for the timing of sales. No options, conversions, or other derivative activity are disclosed, and the filings show continued substantial direct ownership.
TL;DR: Governance-wise, the filing is transparent and includes required explanatory detail about the 10b5-1 plan and ESPP shares.
The Form 4 includes the necessary explanations: plan date, weighted-average sale price disclosure, and a note on ESPP shares included in beneficial ownership totals. The form is signed via attorney-in-fact which is properly indicated. There are no unexplained transfers or complex arrangements; presentation is consistent with routine insider-reporting practices.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 300 | $80.00 | $24K |
| Sale | Common Stock | 3,343 | $80.0085 | $267K |
Footnotes (1)
- The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on March 23, 2025. Represents the weighted average share price of an aggregate total of 3,343 shares sold in the price range of $80.00 to $80.055 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Includes 284 shares acquired under the Issuer's 2022 Employee Stock Purchase Plan on May 14, 2025.
